B cells

[Journal of Gastrointestinal Cancer] Biopsy revealed a lymphoma with strong expression of ALK (granular cytoplasmic), CD138, MUM1, kappa, moderate expression of CD45 and focal expression of CD20, CD79a and PAX5 and lack of expression of CD5, CD3, CD45RO, BCL6, CD10 and EMA.

[Molecular Therapy] Scientists isolated a broad range of promising TCRs targeting multiple antigens for treatment of B-cell malignancies. 28 target genes for B-cell malignancies were selected based on gene expression profiles.

[Scientific Reports] The authors developed an in vitro cell model in which human acute lymphoblastic leukemia cells were grown in co-culture with human derived bone marrow stromal cells or osteoblasts to interrogate a clinically relevant population of treatment refractory cells.

[Cancer Letters] The authors discuss perturbation of cell death in prostate cancer and how new therapeutics could improve treatment outcome in prostate cancer.

[Proceedings of the National Academy of Sciences of the United States of America] To advance the development of natural killer (NK)-based therapies, scientists developed a functional screen to rapidly identify antibodies that can activate NK cells. They displayed antibodies on a mammalian target cell line and probed their ability to stimulate NK cell-mediated cytotoxicity.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.